• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Transl Med . SARS-CoV-2 transmission, persistence of immunity, and estimates of Omicron's impact in South African population cohorts

tetano

Editor, Senior Moderator
Sci Transl Med


. 2022 May 31;eabo7081.
doi: 10.1126/scitranslmed.abo7081. Online ahead of print.
SARS-CoV-2 transmission, persistence of immunity, and estimates of Omicron's impact in South African population cohorts


Kaiyuan Sun[SUP] 1 [/SUP], Stefano Tempia[SUP] 2 3 4 [/SUP], Jackie Kleynhans[SUP] 2 3 [/SUP], Anne von Gottberg[SUP] 2 5 [/SUP], Meredith L McMorrow[SUP] 4 [/SUP], Nicole Wolter[SUP] 2 5 [/SUP], Jinal N Bhiman[SUP] 2 5 [/SUP], Jocelyn Moyes[SUP] 2 3 [/SUP], Mignon du Plessis[SUP] 2 5 [/SUP], Maimuna Carrim[SUP] 2 5 [/SUP], Amelia Buys[SUP] 2 [/SUP], Neil A Martinson[SUP] 6 7 [/SUP], Kathleen Kahn[SUP] 8 [/SUP], Stephen Tollman[SUP] 8 [/SUP], Limakatso Lebina[SUP] 6 [/SUP], Floidy Wafawanaka[SUP] 8 [/SUP], Jacques D du Toit[SUP] 8 [/SUP], Francesc Xavier Gómez-Olivé[SUP] 8 [/SUP], Thulisa Mkhencele[SUP] 2 [/SUP], Cécile Viboud[SUP] 1 [/SUP], Cheryl Cohen[SUP] 2 3 [/SUP]



Affiliations

Abstract

Understanding the build-up of immunity with successive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the epidemiological conditions that favor rapidly expanding epidemics will help facilitate future pandemic control. We analyzed high-resolution infection and serology data from two longitudinal household cohorts in South Africa to reveal high cumulative infection rates and durable cross-protective immunity conferred by prior infection in the pre-Omicron era. Building on the history of past exposures to different SARS-CoV-2 variants and vaccination in the more representative urban cohort given South Africa's high urbanization rate, we used mathematical models to explore the fitness advantage of the Omicron variant and its epidemic trajectory. Modelling suggests the Omicron wave likely infected a large fraction (44% - 81%) of the population, leaving a complex landscape of population immunity primed and boosted with antigenically distinct variants. We project that future SARS-CoV-2 resurgences are likely under a range of scenarios of viral characteristics, population contacts, and residual cross-protection.
 
Back
Top Bottom